secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001493152-24-001660
Event type: debt
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona secures $50M credit facility; $20M funded at close for pz-cel launch prep
--------------------------------------------------------------------------------

- $50M term loan from Avenue Venture Opportunities; $20M drawn at Jan 8 close, $10M committed after pz-cel approval, $20M discretionary.
- Loans mature July 1, 2027; interest at prime+5% (floor 13.5%); final payment fee 5%; minimum $5M cash covenant.
- Warrants issued to lenders for up to ~$2.4M of ABEO stock; exercise price ≤$4.75; expire Jan 2029; cashless exercise allowed.
- Proceeds for pz-cel launch and general corporate; PDUFA for pz-cel BLA set for May 25, 2024 (Priority Review).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000149315224001660/0001493152-24-001660-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000149315224001660/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-001660

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer